These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17382784)

  • 1. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091.
    Brú A
    J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
    Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
    J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
    Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
    Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
    Rini BI; Weinberg V; Bok R; Small EJ
    J Clin Oncol; 2003 Jan; 21(1):99-105. PubMed ID: 12506177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer-producing granulocyte colony-stimulating factor.
    Matsuoka Y; Arai G; Okada Y; Aida J
    Urol Int; 2009; 82(1):113-5. PubMed ID: 19172109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
    Amato RJ; Hernandez-McClain J; Henary H
    Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell Genesys reports long-term survival data in Phase II trial of GVAX.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):245-6. PubMed ID: 12113044
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
    Eggener SE; Raman JD
    J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 16. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of experimental therapeutics for prostate cancer.
    Moon C; Park JC; Chae YK; Yun JH; Kim S
    Cancer Lett; 2008 Aug; 266(2):116-34. PubMed ID: 18440696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
    Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
    J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
    Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
    Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of GM-CSF in advanced prostate cancer.
    Dreicer R; See WA; Klein EA
    Invest New Drugs; 2001; 19(3):261-5. PubMed ID: 11561685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.